Researchers' discovery revives hope in promising lymphoma treatment

October 15, 2012

(Medical Xpress)—Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered the mechanism by which an experimental drug known as GCS-100 removes from lymphoma cells a protein that prevents the cells from responding to chemotherapy.

The discovery revives hope in a that had been tested in clinical trials years before but had been delayed indefinitely. The researchers hope GCS-100 can be combined with chemotherapy to create an effective treatment for diffuse large B-cell (DLBCL), the most common and aggressive form of non-Hodgkin lymphoma, a cancer of the immune system.

The findings are published in the advance online issue of the journal Blood and will appear in a forthcoming print issue of the journal.

The UCLA researchers found that a protein called galectin-3 binds to an enzyme called CD45 on the surface of . This protein–enzyme combination regulates the ' susceptibility to chemotherapy, essentially protecting them from .

Derived from citrus pectin, GCS-100 works outside the cancer cells to remove the protective galectin-3. Once the galectin-3 is removed, a lymphoma cell can be effectively killed by chemotherapy drugs, part of a chain reaction of programmed cancer-cell death known as apoptosis.

Although the researchers knew the drug had shown action against lymphoma cells, the finding that GCS-100 literally removed the barrier to the initiation of cell death by removing galectin-3 from the cell surface was unexpected.

"We let the results guide our ideas, and we were able to establish a mechanism for GCS-100," said the study's first author, Mary Clark, a graduate student researcher in pathology and laboratory medicine. "I am excited to follow the progress of GCS-100 and hope to see its use in the clinic as an adjunct therapy for lymphoma in the near future."

Dr. Linda Baum, a professor of pathology and laboratory medicine and senior researcher on the study, said, "This drug had been abandoned because of the vagaries of the economy. My hope would be to restart this drug in clinical trials and, using this new knowledge, to include it in a more targeted lymphoma therapy."

Early of GCS-100 had shown no known side effects of the drug other than a mild rash in some patients, which other research has demonstrated is the result of the drug also promoting the development of T cells, which are created by the immune system to fight disease.

Explore further: Researchers discover possible drug targets for common non-Hodgkin's lymphoma

Related Stories

Researchers discover possible drug targets for common non-Hodgkin's lymphoma

July 19, 2011
Researchers at the University of Maryland School of Medicine have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large ...

Novel treatment for skin lymphoma

January 17, 2012
Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published today (embargoed for 4 pm) in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer ...

New potential therapeutic target identified for Diffuse Large B-Cell Lymphoma

November 28, 2011
Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have discovered a new potential therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.